OSAKA, Japan, and CAMBRIDGE, Mass., December 21, 2021 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug…Original Article
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
